Established and novel disease-modifying treatments in multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is an autoimmune CNS disorder causing demyelination and neuronal injury.
• Earlier diagnosis is now possible due to new criteria incorporating MRI.
• Individualized treatment for relapsing MS is guided by benefit-risk assessments.

Purpose of the Study:

• To review current and emerging disease-modifying therapies (DMTs) for MS.
• To discuss clinical benefits, mechanisms of action, and safety profiles.
• To outline monitoring strategies for MS patients on DMTs.

Main Methods:

• Review of existing literature on MS DMTs.
• Analysis of efficacy, safety, and administration routes of various treatments.
• Discussion of treatment selection based on disease activity and patient factors.

Main Results:

• Injectable therapies (interferons, glatiramer acetate) have established efficacy and safety.
• Monoclonal antibodies offer targeted mechanisms but carry risks (e.g., PML with natalizumab).
• Oral therapies provide convenience but lack long-term data; initial treatment choice may involve older injectables.

Conclusions:

• Treatment selection for MS requires careful consideration of efficacy, safety, and long-term data.
• Highly inflammatory MS may warrant more potent therapies despite higher risks.
• Ongoing monitoring and potential therapy switching are crucial for managing MS effectively.